Saturday, July 11, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Patents matching “treatment”

2,520 pharma patents match "treatment" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 2,520
Index total 30,257
Page 28 / 105

Quick answer

This filtered view shows 2,520 pharmaceutical patents matching "treatment" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

2,520 results for “treatment” · 30,257 patents in full index Clear search

  1. US 11304916

    Methods and compositions for the treatment of Shiga Toxicosis

    The Board of Regents of the University of Texas System · Granted Apr 19, 2022 · Expires Apr 14, 2042

    granted

  2. US 11299751

    Compositions for the treatment of disease

    VOYAGER THERAPEUTICS, INC. · Granted Apr 12, 2022 · Expires Apr 7, 2042

    granted

  3. US 11299492

    JAK kinase inhibitor compounds for treatment of respiratory disease

    Theravance Biopharma R&D IP, LLC · Granted Apr 12, 2022 · Expires Apr 7, 2042

    granted

  4. US 11298441

    Biodegradable biomimetics of growth plate cartilage for the treatment of physeal injuries

    The Regents of the University of Colorado, a Body Corporate · Granted Apr 12, 2022 · Expires Apr 7, 2042

    granted

  5. US 11291659

    P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD

    Fulcrum Therapeutics, Inc. · Granted Apr 5, 2022 · Expires Mar 31, 2042

    granted

  6. US 11291658

    Use of gaboxadol in the treatment of diabetes and related conditions

    OVID THERAPEUTICS INC. · Granted Apr 5, 2022 · Expires Mar 31, 2042

    granted

  7. US 11292842

    Anti-PD-1 antibodies for treatment of lung cancer

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 5, 2022 · Expires Mar 31, 2042

    granted

  8. US 11285129

    Treatment of circadian rhythm disorders

    VANDA PHARMACEUTICALS INC. · Granted Mar 29, 2022 · Expires Mar 24, 2042

    granted

  9. US 11285194

    Combination immunotherapy approach for treatment of cancer

    Calidi Biotherapeutics, Inc. · Granted Mar 29, 2022 · Expires Mar 24, 2042

    granted

  10. US 11285139

    Treatment of CNS conditions

    Takeda Pharmaceutical Company Limited · Granted Mar 29, 2022 · Expires Mar 24, 2042

    granted

  11. US 11278632

    Engineered nucleases useful for treatment of hemophilia A

    Precision BioSciences, Inc. · Granted Mar 22, 2022 · Expires Mar 17, 2042

    granted

  12. US 11279933

    Antisense oligonucleotides for the treatment of leber congenital amaurosis

    Stichting Radboud universitair medisch centrum · Granted Mar 22, 2022 · Expires Mar 17, 2042

    granted

  13. US 11273226

    Hydrogel prodrug for treatment

    Viking Scientific, Inc. · Granted Mar 15, 2022 · Expires Mar 10, 2042

    granted

  14. US 11273150

    Compositions and methods for the treatment of presbyopia

    Lenz Therapeutics, Inc. · Granted Mar 15, 2022 · Expires Mar 10, 2042

    granted

  15. US 2022072166

    METHOD OF TREATMENT OF NEUROENDOCRINE TUMORS

    ADVANCED ACCELERATOR APPLICATIONS S A [FR] · Granted Mar 10, 2022 · Expires Mar 5, 2042

    granted

  16. US 11266724

    Modified factor VII polypeptides for subcutaneous administration and on-demand treatment

    Catalyst Biosciences, Inc. · Granted Mar 8, 2022 · Expires Mar 3, 2042

    granted

  17. US 11266746

    Therapeutic antitumor combination of a TLR4 ligand with other treatments

    The United Slates of America, as represented by the Secretary, Department of Health and Human Services · Granted Mar 8, 2022 · Expires Mar 3, 2042

    granted

  18. US 11268154

    Methods for the identification, evaluation and treatment of patients having multiple myeloma

    Takeda Pharmaceutical Company Limited · Granted Mar 8, 2022 · Expires Mar 3, 2042

    granted

  19. US 11268077

    Materials and methods for treatment of hemoglobinopathies

    Vertex Pharmaceuticals Incorporated · Granted Mar 8, 2022 · Expires Mar 3, 2042

    granted

  20. US 11266726

    Compositions and methods for the treatment of HER2-expressing solid tumors

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Mar 8, 2022 · Expires Mar 3, 2042

    granted

  21. US 11266622

    Method of treatment

    VANDA PHARMACEUTICALS INC. · Granted Mar 8, 2022 · Expires Mar 3, 2042

    granted

  22. US 11260050

    Combination of cotinine plus antioxidant for treatment-resistant depression and correction of astrocytes functional deficit induced by depression and other neuropathological

    United States Government as represented by the Department of Veterans Affairs · Granted Mar 1, 2022 · Expires Feb 24, 2042

    granted

  23. US 11253509

    Methods of treatment for cystic fibrosis

    Vertex Pharmaceuticals Incorporated · Granted Feb 22, 2022 · Expires Feb 17, 2042

    granted

  24. US 11253522

    Cancer treatment targeted to tumor adaptive responses to protein synthesis stress

    The Regents of the University of California · Granted Feb 22, 2022 · Expires Feb 17, 2042

    granted

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.